LG Chem amends licensing agreement with Rhythm Pharmaceuticals for obesity drug Bivamelagon

The amendment to the exclusive development and commercialization agreement was announced 3 November 2026.

Emmanuel Okoro

Profession Writer

Share on X

Stands on 2 placed sources from 2 publishers.

LG Chem stated on November 3 it had amended an exclusive licensing agreement with Rhythm Pharmaceuticals for development and commercialization of the obesity treatment Bivamelagon.^[1] No additional terms of the amended agreement were disclosed in the announcement. Panelists at the BIX 2026 conference stated one day prior that GLP-1 obesity drug adoption is altering beauty industry product development priorities.^[2]

Proof2 sources · 2 publishers · signed

What this stands on

LG Chem stated on November 3 it amended an exclusive licensing agreement with Rhythm Pharmaceuticals for development and commercialization of obesity treatment Bivamelagon. · Yonhap News AgencySouth Korea
Panelists at BIX 2026 conference stated that GLP-1 obesity drug adoption is altering beauty industry product development priorities · 동아일보

The one we could place publishes from South Korea. 1 could not be placed by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.